Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: FIRMAGON

ATC code: L02BX02

Substances: degarelix, degarelix acetate


As the substance at present is only used by men, analyses on sex or gender differences have not been considered relevant.

Additional information

Degarelix is a Gonadotropin Releasing Hormone Receptor Antagonist used for treatment of advanced hormone dependent prostate cancer [1-2]. There is one experimental study published where degarelix was used for ovarian stimulation (5 healthy women, 5 infertile women) [3]. After a single dose degaralix, all the infertile patients achieved sufficient LH downregulation and completed ovarian stimulation without any LH surge. After blastocyst transferal, pregnancy occurred in three out of five women [3].

Updated: 2018-12-20

Date of litterature search: 2018-12-17


  1. Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-17]. länk
  2. Fass.se [cited 2018-12-06]. länk
  3. Papanikolaou EG, Yarali H, Timotheou E, Grynberg M, Zafeiratis O, Tournaye H et al. A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for . Front Endocrinol (Lausanne). 2018;9(1):25. PubMed
  4. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.] länk
  5. Concise. Kalmar: eHälsomyndigheten. 2015 [cited 2018-12-17.] länk

Authors: Mia von Euler

Reviewed by: Karin Schenck-Gustafsson

Approved by: Karin Schenck-Gustafsson